[Tapentadol: with two mechanisms of action in one molecule effective against nociceptive and neuropathic pain. Preclinical overview].
Tapentadol (3-[(1R, 2R)-3-(dimethylamino)-1-ethyl-2-methylpropyl] phenol) is a centrally acting analgesic of a new substance class for the treatment of severe nociceptive and neuropathic pain. Tapentadol combines μ-opioid receptor (MOR) agonism and noradrenaline reuptake inhibition (NRI) in one molecule. Because of the combined mechanisms of action tapentadol offers a broad therapeutic spectrum for nociceptive as well as neuropathic pain. In different animal models its high efficacy was shown in acute nociceptive, acute and chronic inflammatory as well as in chronic neuropathic pain. Using several preclinical approaches it was shown that the noradrenergic component of tapentadol interacts with the opioid component and that both synergistically contribute to the analgesic effect of the substance. In comparison to known drugs with only one of the two modes of action, tapentadol, despite its high potency, has an improved tolerability profile in the relevant animal models, particularly with regard to gastrointestinal and central side effects. Tapentadol acts directly without metabolic activation and without formation of analgesically relevant metabolites. In different interaction studies a low potential for interactions was shown, thus clinically relevant drug-drug interactions are unlikely. Overall, tapentadol provides a safe pharmacodynamic-pharmacokinetic profile.
Grünenthal GmbH, Präklinische Forschung und Entwicklung, Zieglerstr. 6, 52078 Aachen, Deutschland. thomas.tzschentke@grunenthal.com
T M
TM
Tzschentke
T
T
Christoph
W
W
Schröder
W
W
Englberger
J
J
De Vry
U
U
Jahnel
B Y
BY
Kögel
D018759:Adrenergic Uptake Inhibitors / Q000494:pharmacology*; D000701:Analgesics, Opioid / Q000494:pharmacology*; D000818:Animals; D001921:Brain / Q000187:drug effects; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D006801:Humans; D009020:Morphine / Q000494:pharmacology; D009437:Neuralgia / Q000188:drug therapy* / Q000503:physiopathology*; D009619:Nociceptors / Q000187:drug effects; D009638:Norepinephrine / Q000378:metabolism*; D010147:Pain Measurement / Q000187:drug effects; D010636:Phenols / Q000494:pharmacology*; D017450:Receptors, Opioid, mu / Q000819:agonists*; D013116:Spinal Cord / Q000187:drug effects; D000077432:Tapentadol
D018759:Adrenergic Uptake Inhibitors; D000701:Analgesics, Opioid; D010636:Phenols; D017450:Receptors, Opioid, mu; D009020:Morphine; D000077432:Tapentadol; D009638:Norepinephrine
J Pharmacol Exp Ther. 2007 Oct;323(1):265-76
17656655
Arzneimittelforschung. 2003;53(10):681-7
14650359
Prog Neurobiol. 2002 Apr;66(6):355-474
12034378
Eur J Pain. 2010 Sep;14(8):814-21
20541444
Trends Pharmacol Sci. 2004 Dec;25(12):613-7
15530638
J Pharmacol Exp Ther. 1990 Dec;255(3):1107-16
2262895
Methods Find Exp Clin Pharmacol. 2010 Jan-Feb;32(1):31-8
20383344
Trends Pharmacol Sci. 2006 Jul;27(7):348-54
16762426
Drug Metab Lett. 2008 Jan;2(1):67-75
19356073
Anesthesiology. 1997 Jan;86(1):196-204
9009955
Arch Int Pharmacodyn Ther. 1982 Oct;259(2):222-9
7181579
Curr Med Res Opin. 2009 Mar;25(3):765-76
19203298
Adv Ther. 2010 Jun;27(6):381-99
20556560
Drugs Today (Barc). 2009 Jul;45(7):483-96
19834626
Neurotherapeutics. 2009 Oct;6(4):703-12
19789074
Trends Pharmacol Sci. 1999 Jan;20(1):19-26
10101958
Pain. 2004 Dec;112(3):372-380
15561393
Pain Physician. 2008 Mar-Apr;11(2):201-14
18354712
Curr Med Res Opin. 2009 May;25(5):1095-104
19301989
Neurosci Lett. 2010 Feb 12;470(2):91-4
20026182